

Dag Aarsland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/628921/publications.pdf>

Version: 2024-02-01

571
papers

54,478
citations

1701

104
h-index

1751

212
g-index

630
all docs

630
docs citations

630
times ranked

35727
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
2	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	2.2	2,497
3	Alzheimer's disease. <i>Lancet, The</i> , 2011, 377, 1019-1031.	6.3	2,051
4	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	2.2	1,908
5	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. <i>Nature Genetics</i> , 2019, 51, 404-413.	9.4	1,625
6	Prevalence and Characteristics of Dementia in Parkinson Disease. <i>Archives of Neurology</i> , 2003, 60, 387.	4.9	1,285
7	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
8	Rivastigmine for Dementia Associated with Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2509-2518.	13.9	1,111
9	A systematic review of prevalence studies of dementia in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1255-1263.	2.2	1,060
10	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	3.8	1,009
11	A systematic review of prevalence studies of depression in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 183-189.	2.2	982
12	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324.	2.2	885
13	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.	4.9	705
14	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
15	Predictors of Nursing Home Placement in Parkinson's Disease: A Population-Based, Prospective Study. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 938-942.	1.3	658
16	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824.	2.2	649
17	Dementia with Lewy bodies. <i>Lancet Neurology, The</i> , 2004, 3, 19-28.	4.9	645
18	Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia. <i>Movement Disorders</i> , 2006, 21, 1343-1349.	2.2	541

#	ARTICLE	IF	CITATIONS
19	Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. <i>Movement Disorders</i> , 2007, 22, 1061-1068.	2.2	474
20	Neuropsychiatric symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2175-2186.	2.2	471
21	Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. <i>BMJ: British Medical Journal</i> , 2011, 343, d4065-d4065.	2.4	461
22	Identifying prodromal Parkinson's disease: Pre-motor disorders in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 617-626.	2.2	443
23	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. <i>Lancet Neurology</i> , The, 2012, 11, 697-707.	4.9	432
24	Depression in Parkinson disease—epidemiology, mechanisms and management. <i>Nature Reviews Neurology</i> , 2012, 8, 35-47.	4.9	431
25	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <i>Nature Genetics</i> , 2021, 53, 1276-1282.	9.4	430
26	Lewy body dementias. <i>Lancet</i> , The, 2015, 386, 1683-1697.	6.3	422
27	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurology</i> , The, 2009, 8, 613-618.	4.9	420
28	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.1	391
29	The epidemiology of dementia associated with Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 18-22.	0.3	384
30	Changes in motor subtype and risk for incident dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1123-1130.	2.2	374
31	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.5	365
32	Prevalence and Clinical Correlates of Psychotic Symptoms in Parkinson Disease. <i>Archives of Neurology</i> , 1999, 56, 595.	4.9	363
33	A 12-Year Population-Based Study of Psychosis in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 996-1001.	4.9	323
34	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 528-536.	1.3	321
35	Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies. <i>Archives of Neurology</i> , 2004, 61, 919.	4.9	312
36	Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. <i>Annals of Neurology</i> , 2005, 58, 773-776.	2.8	312

#	ARTICLE	IF	CITATIONS
37	Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1899-1907.	2.2	290
38	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. <i>Nature Genetics</i> , 2015, 47, 445-447.	9.4	283
39	Assessment and treatment of pain in people with dementia. <i>Nature Reviews Neurology</i> , 2012, 8, 264-274.	4.9	270
40	Depression in dementia. <i>Current Opinion in Psychiatry</i> , 2011, 24, 461-472.	3.1	259
41	The Epidemiology of Dementia Associated with Parkinson's Disease. <i>Brain Pathology</i> , 2010, 20, 633-639.	2.1	253
42	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.	4.9	252
43	The cerebrospinal fluid "Alzheimer profile" Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.4	249
44	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 919-927.	2.2	244
45	A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 254-259.	0.9	235
46	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. <i>NeuroImage: Clinical</i> , 2014, 6, 115-125.	1.4	233
47	Risk factors for non-motor symptoms in Parkinson's disease. <i>Lancet Neurology</i> , The, 2018, 17, 559-568.	4.9	225
48	Progression of motor impairment and disability in Parkinson disease. <i>Neurology</i> , 2005, 65, 1436-1441.	1.5	224
49	The Rate of Cognitive Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1906-11.	4.9	222
50	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
51	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 1639-1647.	1.8	211
52	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278.	3.9	209
53	The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 78-84.	1.3	201
54	Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial. <i>PLoS ONE</i> , 2012, 7, e37410.	1.1	201

#	ARTICLE	IF	CITATIONS
55	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
56	Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 937-941.	1.3	197
57	CSF amyloid- β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1080-1086.	0.9	190
58	Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 160-165.	0.9	187
59	Hypertension is a potential risk factor for vascular dementia: systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 661-669.	1.3	184
60	Neuropsychological Profile of Patients with Parkinson's Disease without Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 126-131.	0.7	183
61	Parkinson Disease With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 295-297.	0.6	183
62	The association between motor subtypes and psychopathology in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 379-382.	1.1	181
63	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8754-8759.	3.3	181
64	Are Parkinson's Disease with dementia and Dementia with lewy Bodies the Same Entity?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 137-145.	1.2	180
65	Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 504-514.	1.1	178
66	Glial activation and inflammation along the Alzheimer's disease continuum. <i>Journal of Neuroinflammation</i> , 2019, 16, 46.	3.1	175
67	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.4	174
68	Scales to assess psychosis in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 484-500.	2.2	172
69	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018, 141, 582-595.	3.7	172
70	Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 445-452.	0.7	170
71	Is physical activity a potential preventive factor for vascular dementia? A systematic review. <i>Aging and Mental Health</i> , 2010, 14, 386-395.	1.5	167
72	The prognosis of dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2017, 16, 390-398.	4.9	159

#	ARTICLE	IF	CITATIONS
73	Cognitive Predictors of Dementia in Parkinson's Disease: A Community-Based, 4-Year Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2005, 18, 149-154.	1.2	158
74	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. <i>Neurology</i> , 2014, 82, 2017-2025.	1.5	158
75	Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. <i>Neurology</i> , 2007, 69, 747-754.	1.5	152
76	Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 42-49.	0.9	149
77	Role of Cholinesterase Inhibitors in Parkinson's Disease and dementia with Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 164-171.	1.2	149
78	Prevalence and clinical correlates of apathy in Parkinson's disease: A community-based study. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 295-299.	1.1	146
79	Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. <i>Movement Disorders</i> , 2010, 25, 687-695.	2.2	145
80	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. <i>Circulation</i> , 2015, 131, 2061-2069.	1.6	145
81	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2012, 379, 528-536.	6.3	144
82	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
83	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <i>Brain Pathology</i> , 2015, 25, 401-408.	2.1	144
84	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 823-834.	0.6	144
85	The neuropsychiatry of Parkinson's disease: advances and challenges. <i>Lancet Neurology</i> , 2022, 21, 89-102.	4.9	142
86	The effect of age of onset of PD on risk of dementia. <i>Journal of Neurology</i> , 2007, 254, 38-45.	1.8	141
87	Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 184-191.	1.3	140
88	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
89	Who Suffers Most? Dementia and Pain in Nursing Home Patients: A Cross-sectional Study. <i>Journal of the American Medical Directors Association</i> , 2008, 9, 427-433.	1.2	135
90	Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. <i>International Psychogeriatrics</i> , 2021, 33, 505-514.	0.6	135

#	ARTICLE	IF	CITATIONS
91	Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1097-1102.	0.9	134
92	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. <i>International Psychogeriatrics</i> , 2014, 26, 1083-1098.	0.6	134
93	Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. <i>Molecular Psychiatry</i> , 2015, 20, 1588-1595.	4.1	133
94	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
95	The Response of Agitated Behavior to Pain Management in Persons with Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 708-717.	0.6	132
96	Mild Cognitive Impairment in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 371-378.	2.0	131
97	Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 35-43.	1.0	126
98	Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, 1149-1158.	0.4	126
99	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019, 7, 5.	2.4	125
100	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121
101	Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 371-377.	1.3	119
102	Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1075-1083.	1.3	117
103	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2483-2495.	2.2	115
104	Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S144-S148.	1.1	113
105	Frequency and Correlates of Caregiver-Reported Sleep Disturbances in a Sample of Persons with Early Dementia. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 480-486.	1.3	112
106	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	1.1	110
107	The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 587-590.	1.3	107
108	The Impact of Autonomic Dysfunction on Survival in Patients with Dementia with Lewy Bodies and Parkinson's Disease with Dementia. <i>PLoS ONE</i> , 2012, 7, e45451.	1.1	107

#	ARTICLE	IF	CITATIONS
109	Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. <i>Neurobiology of Disease</i> , 2006, 23, 481-489.	2.1	105
110	Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease. <i>Movement Disorders</i> , 2006, 21, 337-342.	2.2	103
111	Prevalence of late-life depression and gap in mental health service use across European regions. <i>European Psychiatry</i> , 2019, 57, 19-25.	0.1	103
112	A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 58-67.	1.3	102
113	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 431-438.	1.4	102
114	The economic impact of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1541-1544.	2.2	100
115	Identification of Novel α -Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. <i>Neurochemical Research</i> , 2011, 36, 2029-2042.	1.6	99
116	Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 252-258.	1.3	98
117	Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2020, 26, 803-818.	3.5	98
118	Visual rating of white matter hyperintensities in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 223-229.	2.2	97
119	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020, 16, 661-673.	4.9	97
120	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
121	Diffusion Tensor Imaging Surpasses Cerebrospinal Fluid as Predictor of Cognitive Decline and Medial Temporal Lobe Atrophy in Subjective Cognitive Impairment and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 723-736.	1.2	95
122	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <i>Neurobiology of Aging</i> , 2014, 35, 2836-2844.	1.5	94
123	The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 703-717.	1.3	91
124	Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. <i>Frontiers in Systems Neuroscience</i> , 2014, 8, 45.	1.2	90
125	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020, 66, 101714.	7.0	90
126	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. <i>Neuropsychology</i> , 2011, 25, 114-124.	1.0	88

#	ARTICLE	IF	CITATIONS
127	Neuropsychiatric symptoms in patients with multiple sclerosis. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 463-468.	2.2	87
128	Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. <i>Journal of Neurology</i> , 2010, 257, 217-223.	1.8	87
129	Pain treatment of agitation in patients with dementia: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1012-1018.	1.3	87
130	Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. <i>Human Brain Mapping</i> , 2015, 36, 2980-2995.	1.9	87
131	Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1809-1815.	2.2	86
132	Improvement in behavioral symptoms and advance of activity acrophase after short-term bright light treatment in severe dementia. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 343-347.	1.0	81
133	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1064-1068.	0.9	81
134	Mild Cognitive Impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021, 50, 72-80.	0.7	80
135	Pain and Its Relationship to Depression in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 269-275.	0.6	79
136	Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 392-398.	1.3	79
137	Amyloid- β^2 and Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 2605-2619.	1.8	79
138	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 325-331.	0.9	78
139	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008, 62, 1581-1587.	0.8	77
140	Early and Presenting Symptoms of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 202-208.	0.7	77
141	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 287-295.	1.2	77
142	Dementia in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2008, 21, 676-682.	1.8	76
143	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2017, 55, 143-158.	1.5	76
144	The importance of pain management in older people with dementia. <i>British Medical Bulletin</i> , 2014, 111, 139-148.	2.7	75

#	ARTICLE	IF	CITATIONS
145	Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: A cluster randomized trial. <i>European Journal of Pain</i> , 2014, 18, 1490-1500.	1.4	74
146	Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled studyâ€”The Bergen District Nursing Home Study (BEDNURS). <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 889-895.	1.3	73
147	MRI-Based Classification Models in Prediction of Mild Cognitive Impairment and Dementia in Late-Life Depression. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 13.	1.7	73
148	The Effect of Staff Training on Agitation and Use of Restraint in Nursing Home Residents With Dementia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 80-86.	1.1	72
149	Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 633-7.	1.1	72
150	Comparison of Extrapyrâ€”amidal Signs in Dementia With Lewy Bodies and Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 374-379.	0.9	71
151	A Novel Blood Test for the Early Detection of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 121-129.	1.2	71
152	Systematic review of services providing information and/or advice to people with dementia and/or their caregivers. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 628-636.	1.3	71
153	Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 201-207.	2.2	70
154	Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. <i>Movement Disorders</i> , 2016, 31, 1203-1208.	2.2	70
155	Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. <i>Ageing Research Reviews</i> , 2019, 50, 72-80.	5.0	70
156	Grey Matter Changes in Cognitively Impaired Parkinson's Disease Patients. <i>PLoS ONE</i> , 2014, 9, e85595.	1.1	69
157	Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 828-836.	1.3	69
158	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 787-795.	1.2	69
159	Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 46-54.	1.3	67
160	Neuropsychiatric Symptoms in Mild Dementia with Lewy Bodies and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 1-6.	0.7	66
161	Cognitive executive impairment and dopaminergic deficits in <i>de novo</i> Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1802-1808.	2.2	66
162	Neuropsychiatric Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 659-667.	1.5	66

#	ARTICLE	IF	CITATIONS
163	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. <i>NeuroImage</i> , 2009, 47, 2083-2089.	2.1	65
164	The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 1030-1038.	1.3	65
165	Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1361-1369.	1.3	65
166	Apolipoprotein E ϵ 2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1227-1231.	0.9	64
167	Short- and Long-term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 321-331.	0.6	64
168	Health and well-being in care staff and their relations to organizational and psychosocial factors, care staff and resident factors in nursing homes. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 789-797.	1.3	63
169	Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1139-1152.	1.2	63
170	Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 418-424.	1.0	62
171	β -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.5	62
172	Psychosis in Alzheimer disease – mechanisms, genetics and therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2022, 18, 131-144.	4.9	62
173	Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. <i>International Psychogeriatrics</i> , 2009, 21, 216.	0.6	61
174	Gray matter correlations of cognition in incident Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 629-633.	2.2	61
175	Dementia associated with Parkinson's disease: Applying the Movement Disorder Society Task Force criteria. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 621-624.	1.1	61
176	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 428-441.	1.9	61
177	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2018, 65, 18-40.	1.5	61
178	Donepezil for dementia with Lewy bodies: a case study. , 1999, 14, 69-72.		60
179	Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cutoffs. <i>Journal of Internal Medicine</i> , 2014, 275, 317-330.	2.7	60
180	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2019, 15, 400-409.	0.4	60

#	ARTICLE	IF	CITATIONS
181	Amyloid- β^2 and β^1 -synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 758-764.	1.1	59
182	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
183	Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. <i>Neurobiology of Aging</i> , 2006, 27, 433-438.	1.5	58
184	Executive Dysfunction in Mild Cognitive Impairment is Associated with Changes in Frontal and Cingulate White Matter Tracts. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 453-462.	1.2	58
185	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	2.1	58
186	Prevalence of the apolipoprotein E ϵ^4 allele in amyloid β^2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
187	Neuropsychiatric aspects of parkinson's disease. <i>Current Psychiatry Reports</i> , 1999, 1, 61-68.	2.1	57
188	Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. <i>BMJ Open</i> , 2016, 6, e010357.	0.8	57
189	Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020, 32, 705-717.	0.6	57
190	Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study. <i>Neurobiology of Aging</i> , 2010, 31, 104-113.	1.5	56
191	Cerebrospinal fluid amyloid- β and phenotypic heterogeneity in de novo Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 537-543.	0.9	56
192	Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 2011: trend analyses of four data samples. <i>Age and Ageing</i> , 2016, 45, 54-60.	0.7	55
193	Neuropsychiatric Correlates of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 559-563.	0.7	54
194	Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. <i>Drugs and Aging</i> , 2013, 30, 603-611.	1.3	54
195	The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study. <i>British Journal of Psychiatry</i> , 2020, 216, 43-48.	1.7	54
196	The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2005, 112, 386-390.	1.0	53
197	High Prevalence of Orthostatic Hypotension in Mild Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 307-313.	0.7	53
198	Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 930-935.	0.9	53

#	ARTICLE	IF	CITATIONS
199	The Use and Costs of Formal Care in Newly Diagnosed Dementia: A Three-Year Prospective Follow-Up Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 381-388.	0.6	53
200	GBA and APOE ϵ 4 associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019, 9, 7013.	1.6	53
201	APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2009, 22, 166-170.	1.2	51
202	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. <i>Neurobiology of Aging</i> , 2020, 95, 26-45.	1.5	51
203	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 297-301.	2.2	50
204	CSF amyloid $\text{A}\beta$ 38 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 160-164.	0.9	50
205	Long-Term Mortality in a Cohort of Home-Dwelling Elderly with Mild Alzheimer's Disease and Lewy Body Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 161-169.	0.7	50
206	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 247-268.	1.2	50
207	The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS). <i>Journal of the American Medical Directors Association</i> , 2019, 20, 330-339.	1.2	50
208	Synaptic proteins in CSF relate to Parkinson's disease stage markers. <i>Npj Parkinson's Disease</i> , 2017, 3, 7.	2.5	49
209	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 232-241.	1.1	49
210	Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 330-338.	0.7	48
211	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. <i>Brain Pathology</i> , 2019, 29, 63-74.	2.1	48
212	Mental health of people living with dementia in care homes during COVID-19 pandemic. <i>International Psychogeriatrics</i> , 2020, 32, 1253-1254.	0.6	48
213	Depressive Symptoms in Alzheimer's Disease and Lewy Body Dementia: A One-Year Follow-Up Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 143-149.	0.7	47
214	Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. <i>BMJ Open</i> , 2014, 4, e005158-e005158.	0.8	47
215	EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1649-1657.	1.2	47
216	Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci. <i>Scientific Reports</i> , 2018, 8, 18088.	1.6	47

#	ARTICLE	IF	CITATIONS
217	Metabolic patterns across core features in dementia with lewy bodies. <i>Annals of Neurology</i> , 2019, 85, 715-725.	2.8	47
218	COSMOSâ€”improving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial. <i>Implementation Science</i> , 2015, 10, 131.	2.5	46
219	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimerâ€™s and Parkinsonâ€™s Diseases: An EEG Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 339-358.	1.2	45
220	Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinsonâ€™s Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 227-234.	0.7	44
221	Multispectral MRI segmentation of age related white matter changes using a cascade of support vector machines. <i>Journal of the Neurological Sciences</i> , 2012, 322, 211-216.	0.3	44
222	Neuropsychiatric symptoms in dementiaâ€”A role for neuroinflammation?. <i>Brain Research Bulletin</i> , 2014, 108, 88-93.	1.4	44
223	Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 143-152.	1.2	44
224	Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. <i>Frontiers in Psychiatry</i> , 2020, 11, 579934.	1.3	44
225	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 449-461.	1.7	44
226	The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. <i>International Psychogeriatrics</i> , 2012, 24, 1771-1778.	0.6	43
227	Comparing Hippocampal Atrophy in Alzheimer's Dementia and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 44-50.	0.7	43
228	Assessment and Management of Neuropsychiatric Symptoms in Parkinsonâ€™s Disease. <i>CNS Drugs</i> , 2018, 32, 621-635.	2.7	43
229	Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimerâ€™s Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 48-56.	0.6	42
230	A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 3.	3.0	42
231	Cognitive Deficits in Chronic Stroke Patients: Neuropsychological Assessment, Depression, and Self-Reports. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 7, 283-296.	0.6	42
232	Detecting At-Risk Alzheimerâ€™s Disease Cases. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 97-105.	1.2	42
233	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	2.2	42
234	Multivariate classification of patients with Alzheimerâ€™s and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. <i>Journal of Neurology</i> , 2013, 260, 1104-1115.	1.8	41

#	ARTICLE	IF	CITATIONS
235	White matter integrity and cognition in Parkinson's disease: a cross-sectional study. <i>BMJ Open</i> , 2014, 4, e003976.	0.8	41
236	Psychiatric issues in cognitive impairment. <i>Movement Disorders</i> , 2014, 29, 651-662.	2.2	41
237	Cortical Changes Associated with Depression and Antidepressant Use in Alzheimer and Lewy Body Dementia: An MRI Surface-based Morphometric Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 4-13.e1.	0.6	41
238	Unfolded protein response is activated in Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 352-365.	1.8	41
239	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 563-584.	3.3	41
240	Early Discriminatory Diagnosis of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 195-205.	0.7	40
241	Nonlinear decline of mini-mental state examination in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 334-337.	2.2	40
242	Personality Changes after Deep Brain Stimulation in Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	40
243	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinson's Disease</i> , 2019, 5, 7.	2.5	40
244	Clinical Trials of Dementia With Lewy Bodies and Parkinson's Disease Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 492-501.	2.0	39
245	Associations between pain and depression in nursing home patients at different stages of dementia. <i>Journal of Affective Disorders</i> , 2017, 218, 8-14.	2.0	39
246	Systems Biology Approaches to Understand the Host-Microbiome Interactions in Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2020, 14, 716.	1.4	39
247	White Matter Hyperintensities and the Course of Depressive Symptoms in Elderly People with Mild Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 97-111.	0.6	38
248	Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 291-300.	0.6	38
249	Mapping Cortical Atrophy in Parkinson's Disease Patients with Dementia. <i>Journal of Parkinson's Disease</i> , 2013, 3, 69-76.	1.5	38
250	Depression and Synaptic Zinc Regulation in Alzheimer Disease, Dementia with Lewy Bodies, and Parkinson Disease Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 141-148.	0.6	38
251	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 75-86.	0.6	38
252	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	4.5	38

#	ARTICLE	IF	CITATIONS
253	Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 783-792.	1.5	37
254	Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2020, 9, 36.	3.6	37
255	Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1162-1174.	2.4	37
256	Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1084-1090.	1.4	36
257	Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1054-1061.	1.3	36
258	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 273.	2.4	36
259	Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 725-731.	1.3	35
260	The role of pain treatment in managing the behavioural and psychological symptoms of dementia (BPSD). <i>International Journal of Palliative Nursing</i> , 2011, 17, 420-424.	0.2	35
261	Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia. <i>International Psychogeriatrics</i> , 2018, 30, 395-407.	0.6	35
262	Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 935-946.	1.3	35
263	Trajectories of depressive symptoms and associated patterns of cognitive decline. <i>Scientific Reports</i> , 2020, 10, 20888.	1.6	35
264	FMR1 Alleles in Parkinson's Disease: Relation to Cognitive Decline and Hallucinations, A Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007, 20, 89-92.	1.2	34
265	Validation of the Unified Parkinson's Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 183-186.	1.1	34
266	Neuroanatomical correlates of late-life depression and associated cognitive changes. <i>Neurobiology of Aging</i> , 2015, 36, 3090-3099.	1.5	34
267	Higher Frequency and Complexity of Sleep Disturbances in Dementia with Lewy Bodies as Compared to Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2016, 16, 152-160.	0.8	34
268	Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 275-294.	0.9	34
269	Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 927.	1.0	33
270	Clinical and Neuropsychological Differences between Mild Parkinson's Disease Dementia and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 212-220.	0.6	33

#	ARTICLE	IF	CITATIONS
271	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. PLoS ONE, 2018, 13, e0201964.	1.1	33
272	Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. Journal of Neural Transmission, 2019, 126, 327-337.	1.4	33
273	Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders, 2011, 26, 824-829.	2.2	32
274	Comorbidity profile in dementia with Lewy bodies versus Alzheimer's disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. Alzheimer's Research and Therapy, 2014, 6, 65.	3.0	32
275	Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 335-343.	0.6	32
276	Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. Acta Psychiatrica Scandinavica, 2016, 134, 430-440.	2.2	32
277	Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12164.	1.2	32
278	Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment. Acta Psychiatrica Scandinavica, 2015, 131, 139-147.	2.2	30
279	Psychosis in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 585-622.	0.9	30
280	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745.	1.6	30
281	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	4.1	30
282	Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. Acta Psychiatrica Scandinavica, 2011, 123, 459-465.	2.2	29
283	Classifying Dementia Using Local Binary Patterns from Different Regions in Magnetic Resonance Images. International Journal of Biomedical Imaging, 2015, 2015, 1-14.	3.0	29
284	Anthocyanins protect from complex I inhibition and APP ^{swe} mutation through modulation of the mitochondrial fission/fusion pathways. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 2110-2118.	1.8	29
285	Loss of dopamine transporter binding and clinical symptoms in dementia with Lewy pathology. Movement Disorders, 2016, 31, 118-125.	2.2	29
286	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. Neurobiology of Aging, 2016, 42, 124-131.	1.5	29
287	Reduced Walking Speed in Subjective and Mild Cognitive Impairment: A Cross-Sectional Study. Journal of Geriatric Physical Therapy, 2019, 42, E122-E128.	0.6	29
288	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. Journal of Parkinson's Disease, 2021, 11, 1209-1219.	1.5	29

#	ARTICLE	IF	CITATIONS
289	Familial Parkinson's disease: a community-based study. <i>European Journal of Neurology</i> , 2003, 10, 159-163.	1.7	28
290	New Therapeutic Strategies for Lewy Body Dementias. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 68.	2.0	28
291	Frailty in Older Adults with Mild Dementia: Dementia with Lewy Bodies and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 9, 176-183.	0.6	28
292	Psychosis in Alzheimer's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 57.	2.0	28
293	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 89.	3.0	28
294	SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics. <i>Scientific Reports</i> , 2017, 7, 41929.	1.6	27
295	Combinatory microRNA serum signatures as classifiers of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 202-210.	1.1	27
296	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 913-919.	1.2	27
297	(¹²³ I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. <i>BMJ Open</i> , 2013, 3, e002642.	0.8	26
298	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β 2-amyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016, 9, 84.	1.3	26
299	Investigating the relationship between age of onset of depressive disorder and cognitive function. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 38-46.	1.3	26
300	Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>European Journal of Epidemiology</i> , 2021, 36, 89-101.	2.5	26
301	Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 523-529.	1.2	25
302	Increased Transforming Growth Factor β 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble A β 42 Load. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 157-166.	1.2	25
303	Validity and Cultural Generalisability of a 5-Minute AI-Based, Computerised Cognitive Assessment in Mild Cognitive Impairment and Alzheimer's Dementia. <i>Frontiers in Psychiatry</i> , 2021, 12, 706695.	1.3	25
304	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 101-110.	1.2	24
305	Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study. <i>Npj Parkinson's Disease</i> , 2016, 2, 15030.	2.5	24
306	Cerebrospinal fluid neurogranin site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 617-627.	1.8	24

#	ARTICLE	IF	CITATIONS
307	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020, 91, 88-111.	1.5	24
308	Resting-state EEG alpha/theta ratio related to neuropsychological test performance in Parkinson's Disease. <i>Clinical Neurophysiology</i> , 2021, 132, 756-764.	0.7	24
309	Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: Etiology and management. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 345-354.	2.0	23
310	Rivastigmine in the Treatment of Dementia Associated with Parkinson's Disease: Effects on Activities of Daily Living. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 510-515.	0.7	23
311	Impaired synaptic function is linked to cognition in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 700-713.	1.7	23
312	Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study. <i>Movement Disorders</i> , 2006, 21, 2170-2174.	2.2	22
313	Familial Occurrence of Dementia and Parkinsonism. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 288-295.	0.7	22
314	Core and Suggestive Symptoms of Dementia with Lewy Bodies Cluster in Persons with Mild Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 317-324.	0.7	22
315	Medial Temporal Lobe Atrophy and Depressive Symptoms in Elderly Patients With and Without Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015, 28, 40-48.	1.2	22
316	Signs of Imminent Dying and Change in Symptom Intensity During Pharmacological Treatment in Dying Nursing Home Patients: A Prospective Trajectory Study. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 821-827.	1.2	22
317	Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 183-192.	1.3	22
318	Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). <i>Drugs and Aging</i> , 2018, 35, 545-558.	1.3	22
319	The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia With Lewy Bodies and Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 604-609.	1.2	22
320	The combined effect of amyloid- β and tau biomarkers on brain atrophy in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020, 27, 102333.	1.4	22
321	Evaluating Rivastigmine in Mild-to-Moderate Parkinson's Disease Dementia Using ADAS-Cog Items. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 407-413.	0.9	21
322	A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 53.	3.0	21
323	Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways. <i>CNS Drugs</i> , 2019, 33, 143-160.	2.7	21
324	Mediating effect of mutuality on caregiver burden in Parkinson's disease partners. <i>Aging and Mental Health</i> , 2020, 24, 1421-1428.	1.5	21

#	ARTICLE	IF	CITATIONS
325	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2257-2263.	1.3	21
326	Benzodiazepines and antidepressants: Effects on cognitive and functional decline in Alzheimer's disease and Lewy body dementia. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 917-925.	1.3	21
327	Effects of Rivastigmine in Alzheimer's Disease Patients with and Without Hallucinations. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 301-311.	1.2	20
328	β -synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010, 22, 321-327.	0.6	20
329	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 206-213.	1.3	20
330	Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 573-582.	1.3	20
331	Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia. <i>International Psychogeriatrics</i> , 2021, 33, 1217-1228.	0.6	20
332	Management of Parkinson's Disease Dementia. <i>Drugs and Aging</i> , 2006, 23, 807-822.	1.3	19
333	Cerebrospinal Fluid Levels of sAPP β and sAPP α in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-6.	1.1	19
334	A Pilot Study Examining Associations between DYRK1A and β -Synuclein Dementias. <i>Neurodegenerative Diseases</i> , 2012, 10, 229-231.	0.8	19
335	Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 580-586.	0.6	19
336	A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD). <i>Journal of the American Medical Association</i> , 2015, 316, 316-322.	1.2	19
337	Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 621-630.	1.2	19
338	Cognitive Interventions in Parkinson's Disease: Where We Want to Go within 20 Years. <i>Journal of Parkinson's Disease</i> , 2018, 8, S107-S113.	1.5	19
339	Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 728-730.	0.9	19
340	Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2020, 268, 2769-2779.	1.8	19
341	A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1471-1487.	1.3	19
342	A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 53.	3.0	19

#	ARTICLE	IF	CITATIONS
343	Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 345-355.	1.2	19
344	Lexical and Nonlexical Spelling Deficits in Dementia of the Alzheimer Type. <i>Brain and Language</i> , 1996, 52, 551-563.	0.8	18
345	Subthreshold depression in patients with Parkinson's disease and dementiaâ€”clinical and demographic correlates. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 980-985.	1.3	18
346	Grey matter atrophy in early versus late dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 620-625.	1.1	18
347	Effect of Vascular Risk Factors on the Progression of Mild Alzheimerâ€™s Disease and Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 575-584.	1.2	18
348	European DLB consortium: diagnostic and prognostic biomarkers in dementia with Lewy bodies, a multicenter international initiative. <i>Neurodegenerative Disease Management</i> , 2019, 9, 247-250.	1.2	18
349	Temporal Relationship Between Depressive Symptoms and Cognition in Mid and Late Life: A Longitudinal Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1108-1113.	1.2	18
350	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	1.5	18
351	Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. <i>Advances in Neurology</i> , 2005, 96, 56-64.	0.8	18
352	Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimerâ€™s Disease are Associated with Parkinsonism. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1277-1285.	1.2	17
353	Determinants of Dyadic Relationship and Its Psychosocial Impact in Patients with Parkinsonâ€™s Disease and Their Spouses. <i>Parkinson's Disease</i> , 2017, 2017, 1-9.	0.6	17
354	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018, 33, 528-536.	2.2	17
355	Montreal Cognitive Assessment in a 63- to 65-year-old Norwegian Cohort from the General Population: Data from the Akershus Cardiac Examination 1950 Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 7, 318-327.	0.6	17
356	Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 83.	3.0	17
357	Association of depressive symptoms and subjective memory complaints with the incidence of cognitive impairment in older adults with high blood pressure. <i>European Geriatric Medicine</i> , 2019, 10, 413-420.	1.2	17
358	Selecting Remote Measurement Technologies to Optimize Assessment of Function in Early Alzheimer's Disease: A Case Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 582207.	1.3	17
359	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. <i>Brain</i> , 2022, 145, 1757-1762.	3.7	17
360	Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. <i>Npj Genomic Medicine</i> , 2017, 2, 24.	1.7	16

#	ARTICLE	IF	CITATIONS
361	Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 995-1005.	1.2	16
362	Association of Malnutrition with Functional and Cognitive Trajectories in People Living with Dementia: A Five-Year Follow-Up Study. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1713-1722.	1.2	16
363	Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ϵ 4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 567-576.	1.2	15
364	Classifying Alzheimer's disease, Lewy body dementia, and normal controls using 3D texture analysis in magnetic resonance images. <i>Biomedical Signal Processing and Control</i> , 2017, 33, 19-29.	3.5	15
365	Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 929-939.	1.2	15
366	A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 124.	1.1	15
367	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <i>Journal of Parkinson's Disease</i> , 2021, 11, 299-307.	1.5	15
368	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014, 3, 108.	0.8	15
369	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018, 15, 883-891.	0.7	15
370	Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs. <i>Programme Grants for Applied Research</i> , 2020, 8, 1-98.	0.4	15
371	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. <i>Neuroscience Letters</i> , 2015, 594, 137-143.	1.0	14
372	Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 464.e1-464.e7.	1.2	14
373	Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> , 2016, 87, 1045-1051.	1.5	14
374	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 373-386.	1.2	14
375	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 283-293.	0.7	14
376	Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 520-527.	2.2	14
377	Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia – A Pilot Study. <i>Frontiers in Genetics</i> , 2019, 10, 536.	1.1	14
378	Depression in Parkinson's disease. <i>Acta Psychiatrica Scandinavica</i> , 2002, 106, 161-162.	2.2	13

#	ARTICLE	IF	CITATIONS
379	Mania After Administration of Cholinesterase Inhibitors in Patients With Dementia and Comorbid Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 254-256.	0.7	13
380	Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia. <i>International Journal of Tryptophan Research</i> , 2019, 12, 117864691987788.	1.0	13
381	Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 32-36.	0.8	13
382	Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1143-1155.	1.2	13
383	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12098.	1.2	13
384	Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 573-584.	0.6	13
385	Psychiatric aspects of Parkinson's disease. <i>Current Opinion in Psychiatry</i> , 2005, 18, 335-341.	3.1	12
386	Relationship between Orthostatic Hypotension and White Matter Hyperintensity Load in Older Patients with Mild Dementia. <i>PLoS ONE</i> , 2012, 7, e52196.	1.1	12
387	Patterns of carer distress over time in mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 987-993.	1.3	12
388	The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1421-1428.	1.3	12
389	Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease. <i>Scientific Reports</i> , 2019, 9, 17222.	1.6	12
390	Body mass index, performance on activities of daily living and cognition: analysis in two different populations. <i>BMC Geriatrics</i> , 2021, 21, 177.	1.1	12
391	Polypharmacy is associated with functional decline in Alzheimer's disease and Lewy body dementia. <i>Archives of Gerontology and Geriatrics</i> , 2021, 96, 104459.	1.4	12
392	Person-centred care and care mapping in dementia. <i>Lancet Neurology</i> , The, 2009, 8, 302-303.	4.9	11
393	Galantamine versus Risperidone for Agitation in People with Dementia: A Randomized, Twelve-Week, Single-Center Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 234-244.	0.7	11
394	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 387-393.	1.2	11
395	Psychometric properties of the mutuality scale in Swedish dyads with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 122-128.	1.0	11
396	The Mental and Physical Health Profiles of Older Adults Who Endorse Elevated Autistic Traits. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1726-1737.	2.4	11

#	ARTICLE	IF	CITATIONS
397	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2022, 115, 88-108.	1.5	11
398	Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 070615220219002-???	1.8	10
399	Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. <i>Journal of Parkinson's Disease</i> , 2016, 6, 413-421.	1.5	10
400	The relationship between the frequency of number puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 932-940.	1.3	10
401	Clinical factors associated with progression to dementia in people with late-life depression: a cohort study of patients in secondary care. <i>BMJ Open</i> , 2020, 10, e035147.	0.8	10
402	The association between aspects of carer distress and time until nursing home admission in persons with Alzheimer's disease and dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2021, 33, 337-345.	0.6	10
403	Traumatic life experiences and post-traumatic stress symptoms in middle-aged and older adults with and without autistic traits. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	10
404	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 14.	3.0	10
405	Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 349-361.	1.2	9
406	Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1321-1330.	1.2	9
407	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 153.	3.0	9
408	Association between physical activity and cognition in Mexican and Korean older adults. <i>Archives of Gerontology and Geriatrics</i> , 2020, 89, 104047.	1.4	9
409	An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-ADLB). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12171.	1.8	9
410	Presynaptic accumulation of α -synuclein causes synaptopathy and progressive neurodegeneration in <i>Drosophila</i> . <i>Brain Communications</i> , 2021, 3, fcab049.	1.5	9
411	Serum tyrosine is associated with better cognition in Lewy body dementia. <i>Brain Research</i> , 2021, 1765, 147481.	1.1	9
412	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. <i>Scientific Reports</i> , 2021, 11, 20375.	1.6	9
413	Screening for Alzheimer's Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1621-1631.	1.2	8
414	REM Sleep Behavior Disorder Is Not Associated with a More Rapid Cognitive Decline in Mild Dementia. <i>Frontiers in Neurology</i> , 2017, 8, 375.	1.1	8

#	ARTICLE	IF	CITATIONS
415	CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 109-110.	0.9	8
416	Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2020, 11, 916.	1.1	8
417	Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies. <i>Frontiers in Neurology</i> , 2021, 12, 679984.	1.1	8
418	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2022, 152, 105251.	1.9	8
419	Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology. <i>Journal of Neurology</i> , 2022, 269, 3636-3652.	1.8	8
420	No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. <i>Neuroscience Letters</i> , 2012, 531, 1-4.	1.0	7
421	Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 281-290.	0.6	7
422	A new tool to identify patients with Parkinson's disease at increased risk of dementia. <i>Lancet Neurology</i> , The, 2017, 16, 576-578.	4.9	7
423	Novel evidence associates higher plasma α -synuclein levels and cognitive impairment in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 808-808.	0.9	7
424	Mediating Effect of Mutuality on Health-Related Quality of Life in Patients with Parkinson's Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-8.	0.6	7
425	Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 761-774.	1.2	7
426	The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. <i>Multivariate Behavioral Research</i> , 2021, 56, 70-85.	1.8	7
427	The Mental and Physical Health of Older Adults With a Genetic Predisposition for Autism. <i>Autism Research</i> , 2020, 13, 641-654.	2.1	7
428	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 397-412.	0.8	6
429	Are anxiety disorders undertreated in patients with multiple sclerosis?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 372-373.	2.7	6
430	Cognitive and psychiatric disturbances in Parkinson's disease. <i>Ageing Health</i> , 2011, 7, 123-142.	0.3	6
431	Harnessing the power of cohort studies for dementia research. <i>Journal of Public Mental Health</i> , 2015, 14, 8-17.	0.8	6
432	Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12235.	1.2	6

#	ARTICLE	IF	CITATIONS
433	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e02086.	1.0	6
434	Regression-based norms for the FAS phonemic fluency test for ages 40-84 based on a Norwegian sample. <i>Applied Neuropsychology Adult</i> , 2023, 30, 159-168.	0.7	6
435	Muscle Volume and Intramuscular Fat of the Tongue Evaluated With MRI Predict Malnutrition in People Living With Dementia: A 5-Year Follow-up Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 228-234.	1.7	6
436	Light, sleep-wake rhythm, and behavioural and psychological symptoms of dementia in care home patients: Revisiting the sundowning syndrome. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	6
437	Prodromal Dementia With Lewy Bodies and Recurrent Panic Attacks as the First Symptom: A Case Report. <i>Frontiers in Neurology</i> , 2022, 13, 839539.	1.1	6
438	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. <i>Translational Neurodegeneration</i> , 2022, 11, 24.	3.6	6
439	In Brief Neuropsychological Assessment, Amnesic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 715-723.	1.2	5
440	Psychiatric and neuropsychiatric syndromes and COVID-19. <i>Lancet Psychiatry</i> , 2020, 7, 663-664.	3.7	5
441	Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer's Disease. <i>Brain Sciences</i> , 2020, 10, 68.	1.1	5
442	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European DLB consortium project. <i>Alzheimer's and Dementia</i> , 2021, 17, 1277-1286.	0.4	5
443	Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1825-1839.	1.2	5
444	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021, 106, 304.e1-304.e3.	1.5	5
445	Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1117-1127.	1.2	5
446	Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia. <i>Neuropsychology</i> , 2020, 34, 851-861.	1.0	5
447	Are subtypes of affective symptoms differentially associated with change in cognition over time: A latent class analysis. <i>Journal of Affective Disorders</i> , 2022, 309, 437-445.	2.0	5
448	Frailty in Parkinson's disease and its association with early dementia: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2022, 99, 51-57.	1.1	5
449	Protocol for Rhapsody: a longitudinal observational study examining the feasibility of speech phenotyping for remote assessment of neurodegenerative and psychiatric disorders. <i>BMJ Open</i> , 2022, 12, e061193.	0.8	5
450	Biomarkers of PD progression. <i>Neurology</i> , 2010, 75, 1036-1037.	1.5	4

#	ARTICLE	IF	CITATIONS
451	Persistence and Prognostic Implications of Orthostatic Hypotension in Older Individuals with Mild-to-Moderate Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 283-296.	0.6	4
452	[P3â€“017]: HEADWAYâ€“DLB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRDINE (RVTâ€“101) IN DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P936.	0.4	4
453	Hippocampal subfields and decline in activities of daily living in Alzheimerâ€™s disease and dementia with Lewy bodies. <i>Neurodegenerative Disease Management</i> , 2020, 10, 357-367.	1.2	4
454	Risk of Hospitalization in Patients with Alzheimerâ€™s Disease and Lewy Body Dementia: Time to and Length of Stay. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1221-1230.	1.2	4
455	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021, 146, 111223.	1.2	4
456	Isoelectric point region plâ‰“7.4 as a treasure island of abnormal proteoforms in blood. <i>Discoveries</i> , 2016, 4, e67.	1.5	4
457	Risky drinking and cognitive impairment in community residents aged 50 and over. <i>Aging and Mental Health</i> , 2022, 26, 2432-2439.	1.5	4
458	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts. <i>British Journal of Psychiatry</i> , 2022, 221, 722-731.	1.7	4
459	Psychiatric Aspects of Parkinsonâ€™s Disease, Parkinsonâ€™s Disease with Dementia, and Dementia with Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 111-111.	1.2	3
460	Many roads lead to Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 122-123.	2.2	3
461	Impulse control disorders and related behaviors. , 2013, , 140-152.		3
462	Neuropsychiatric and cognitive disorders in other parkinsonian disorders. , 2013, , 261-274.		3
463	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014, 121, 71-78.	1.4	3
464	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review â€“ CORRIGENDUM. <i>International Psychogeriatrics</i> , 2014, 26, 1099-1099.	0.6	3
465	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinsonâ€™s Disease Dementia. <i>Journal of Parkinson's Disease</i> , 2016, 6, 733-739.	1.5	3
466	Components of the choline oxidation pathway modify the association between the apolipoprotein Î¼4 gene variant and cognitive decline in patients with dementia. <i>Brain Research</i> , 2020, 1726, 146519.	1.1	3
467	Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12152.	1.2	3
468	Self-harm and Suicidality Experiences of Middle-Age and Older Adults With vs. Without High Autistic Traits. <i>Journal of Autism and Developmental Disorders</i> , 2023, 53, 3034-3046.	1.7	3

#	ARTICLE	IF	CITATIONS
469	Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer's Disease in Nordic Populations. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1533-1544.	1.2	3
470	OS-03-04: Clinical characteristics and course of dlb: Results from a large longitudinal multicentre cohort. <i>Alzheimer's and Dementia</i> , 2015, 11, P320.	0.4	2
471	Lewy Body Dementias. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 85-100.	0.4	2
472	P3-54: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATION-BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1335.	0.4	2
473	Commentary: A posterior-to-anterior shift of brain functional dynamics in aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 341.	1.7	2
474	The ANeED study: Ambroxol in new and early dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e042589.	0.4	2
475	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539.	0.4	2
476	Colombian consortium for the study of Lewy body dementia COL-DLB. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116807.	0.3	2
477	Parkinson's disease dementia and dementia with Lewy bodies " epidemiology, risk factors and biomarkers. <i>Norsk Epidemiologi</i> , 2012, 22, .	0.2	2
478	Tongue muscle mass is associated with total grey matter and hippocampal volumes in Dementia with Lewy Bodies. <i>Archives of Gerontology and Geriatrics</i> , 2022, 100, 104647.	1.4	2
479	Timed Up and Go in People with Subjective Cognitive Decline Is Associated with Faster Cognitive Deterioration and Cortical Thickness. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 63-72.	0.7	2
480	Specific depressive symptoms are related with different patterns of alcohol use in community-dwelling older adults. <i>Archives of Gerontology and Geriatrics</i> , 2022, 101, 104696.	1.4	2
481	Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, , 1-12.	1.5	2
482	Body mass index trajectories and associations with cognitive decline in people with Lewy body dementia and Alzheimer's disease. <i>Health Science Reports</i> , 2022, 5, e590.	0.6	2
483	Basal ganglia diseases and geriatric psychiatry: a new approach. <i>Current Opinion in Psychiatry</i> , 2003, 16, 621-627.	3.1	1
484	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 397-397.	0.8	1
485	Rivastigmine in Parkinson's Disease Dementia. <i>CNS Drugs</i> , 2006, 20, 748-750.	2.7	1
486	Current perspectives in dementia with Lewy bodies. <i>Aging Health</i> , 2006, 2, 461-472.	0.3	1

#	ARTICLE	IF	CITATIONS
487	Clinical aspects of Parkinson dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 303-306.	1.0	1
488	Nonmotor Symptoms of Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-2.	0.6	1
489	Biomarkers for dementia diagnosis: differentiating DLB and FTD may be difficult. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1037-1037.	0.9	1
490	O3-10-01: Clinical course of Lewy-body disease: Cognitive decline and mortality. , 2013, 9, P537-P538.		1
491	Using biomarkers to disentangle different causes of Parkinsonism. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 119-119.	0.9	1
492	Early cognitive impairment. , 0, , 163-176.		1
493	Neuropsychiatric aspects of the on/off phenomenon. , 2013, , 275-284.		1
494	A 5-YEAR LONGITUDINAL STUDY OF PATIENTS WITH DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE. , 2014, 10, P261-P261.		1
495	[P1â€™299]: AN EVALUATION OF PREDICTORS AND COGNITIVE DECLINE ASSOCIATED WITH PERSISTENT AND TRANSIENT PSYCHOTIC SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P367.	0.4	1
496	[P1â€™564]: RISK AND DURATION OF HOSPITALIZATION IN DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P510.	0.4	1
497	P1â€™658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS. Alzheimer's and Dementia, 2018, 14, P595.	0.4	1
498	Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. Journal of Alzheimer's Disease, 2019, 68, 239-253.	1.2	1
499	The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein Îµ4 Allele Variant in Patients With Dementia. International Journal of Tryptophan Research, 2019, 12, 117864691988563.	1.0	1
500	A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey. Frontiers in Psychiatry, 2020, 11, 602480.	1.3	1
501	Cleaved Annexin A1 is elevated in neurodegenerative dementia and is associated with pathological burden of amyloid and inflammatory cytokines. Alzheimer's and Dementia, 2020, 16, e037636.	0.4	1
502	Linking electronic dementia care records to national inpatient data in dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes. Alzheimer's and Dementia, 2020, 16, e039139.	0.4	1
503	Clinical factors associated with progression to dementia in people with late-life depression: A cohort study of patients in secondary care. Alzheimer's and Dementia, 2020, 16, e039147.	0.4	1
504	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808.	0.4	1

#	ARTICLE	IF	CITATIONS
505	Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, e043593.	0.4	1
506	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson's and Lewy body diseases. <i>Alzheimer's and Dementia</i> , 2020, 16, e045886.	0.4	1
507	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022, 34, 214-223.	0.9	1
508	The impact of the COVID-19 pandemic on cognitive health. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
509	A remote digital tool for diagnosis and monitoring of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
510	Self and informant-rated mild behavioral impairment and genetic risk for AD: The respondent matters. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
511	Augmented reality to detect subtle alterations in the early stages of Alzheimer's disease: Preliminary results of the RADAR-AD study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
512	Gait characteristics in preclinical Alzheimer's disease: Preliminary results of the RADAR-AD study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
513	Role of Neuropsychiatric Assessment in Diagnosis and Research. , 2005, , 163-183.		0
514	Rivastigmine for the treatment of Parkinson's disease dementia. <i>Aging Health</i> , 2010, 6, 277-284.	0.3	0
515	Developing predictive biomarkers for dementia of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1661-1663.	1.4	0
516	Man with fluctuating confusion. , 0, , 148-154.		0
517	Authors' reply to McShane and Regnard. <i>BMJ: British Medical Journal</i> , 2011, 343, d5356-d5356.	2.4	0
518	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2011, 1, 187-189.	1.2	0
519	Reply: Neuropsychiatric symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 191-192.	2.2	0
520	Parkinson's disease: pathology, anatomy, and behavior. , 0, , 14-24.		0
521	The boundaries of Parkinson's disease dementia and dementia with Lewy bodies. , 0, , 40-52.		0
522	Clinical assessment: mood and motivation. , 0, , 65-72.		0

#	ARTICLE	IF	CITATIONS
523	Imaging and behavior in Parkinson's disease: structural imaging. , 0, , 73-88.		0
524	Imaging and behavior in Parkinson's disease: functional imaging. , 0, , 89-96.		0
525	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
526	Apathy. , 0, , 131-139.		0
527	Parkinson's disease dementia. , 0, , 177-191.		0
528	Sleep disturbances. , 0, , 192-210.		0
529	Surgical treatment and behavior. , 0, , 230-243.		0
530	Clinical trials for psychotropic agents in Parkinson's disease using psychosis as a model. , 0, , 244-254.		0
531	Treatment of neuropsychiatric disturbances in Parkinson's disease: future prospects and strategies. , 0, , 285-291.		0
532	The genetics of behavior and cognition in Parkinson's disease. , 0, , 25-39.		0
533	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2013, 3, 105-107.	1.2	0
534	P2-135: CSF a β 42 is related to cortical metabolism (FDG-PET) in non-demented parkinson's disease patients. , 2015, 11, P536-P537.		0
535	Reply to letter to the editor "Independent application of MoCA/MMSE conversion" by Armstrong et al.. Movement Disorders, 2015, 30, 1711-1711.	2.2	0
536	O3-04-02: Clinico-Pathologic Correlations in Dementia with Lewy Bodies (DLB): A Prospective Cohort Study. Alzheimer's and Dementia, 2016, 12, P291.	0.4	0
537	Non-Alzheimer Dementias. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 247-248.	1.2	0
538	[P1-235]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUBUNITS IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P333.	0.4	0
539	[P3-243]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1033.	0.4	0
540	[P4-154]: DETECTING AT-RISK CASES FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1317o.4		0

#	ARTICLE	IF	CITATIONS
541	[P1â€“456]: INCREASED PSER129 Î±â€“SYNUCLEIN IS ASSOCIATED WITH SYNAPTIC DEFICITS IN DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2017, 13, P461.	0.4	0
542	[P2â€“204]: RPT6, 20S Î±â€“6 AND Î±â€“3 PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH COGNITIVE DECLINE IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS. Alzheimer's and Dementia, 2017, 13, P684.	0.4	0
543	[F5â€“01â€“03]: CLINICOâ€“PATHOLOGIC ASSOCIATIONS IN DLB: RELEVANCE FOR DIAGNOSIS AND TREATMENT. Alzheimer's and Dementia, 2017, 13, P1444.	0.4	0
544	P3â€“243: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1165.	0.4	0
545	P1â€“523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBIâ€“) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P532.	0.4	0
546	P1â€“151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P335.	0.4	0
547	P2â€“483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER. Alzheimer's and Dementia, 2018, 14, P914.	0.4	0
548	O1â€“10â€“04: ABNORMALITIES OF RESTING STATE FUNCTIONAL CORTICAL CONNECTIVITY IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S AND LEWY BODY DISEASES: AN EEG STUDY. Alzheimer's and Dementia, 2018, 14, P244.	0.4	0
549	P3â€“001: A RANDOMIZED, PLACEBOâ€“CONTROLLED TRIAL TO INVESTIGATE SAFETY OF BUPRENORPHINE TRANSDERMAL SYSTEM FOR PAIN MANAGEMENT IN PEOPLE WITH DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1062.	0.4	0
550	Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. Alzheimer's and Dementia, 2020, 16, e039145.	0.4	0
551	Decreased JNK3 levels are associated with amyloid plaque and neurofibrillary tangles in dementia patients. Alzheimer's and Dementia, 2020, 16, e039231.	0.4	0
552	Neuropsychiatric symptoms correlated with functional trajectories among people living with Alzheimer's disease dementia and Lewy body dementia. Alzheimer's and Dementia, 2020, 16, e041881.	0.4	0
553	A systematic review on the physical and mental health risk factors of mild cognitive impairment and Alzheimer's disease in military veterans. Alzheimer's and Dementia, 2020, 16, e042913.	0.4	0
554	A prospective longâ€“term study of TDPâ€“43 pathology in Alzheimer's disease aggression. Alzheimer's and Dementia, 2020, 16, e043659.	0.4	0
555	Neuropsychiatric symptoms and cognitive decline: Trait or state effects?. Alzheimer's and Dementia, 2020, 16, e043789.	0.4	0
556	Functional alterations in visual networks underlie differences in the phenomenology of visual hallucinations in Lewy body disease. Alzheimer's and Dementia, 2020, 16, e045102.	0.4	0
557	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson's and Lewy body diseases. Alzheimer's and Dementia, 2020, 16, e045811.	0.4	0
558	Plasmaâ€“based biomarkers for AÎ² and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046490.	0.4	0

#	ARTICLE	IF	CITATIONS
559	The reliability of a deep learning model in external memory clinic MRI data: A multi-cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042969.	0.4	0
560	Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment. <i>Revista Colombiana De Psiquiatría</i> , 2021, , .	0.1	0
561	Cognitive impairment and dementia in Parkinson's disease. , 2005, , 657-663.		0
562	Pharmacological management of neuropsychiatric symptoms in people with dementia. , 2009, , 105-116.		0
563	The Lewy Body Dementias: Dementia with Lewy Bodies and Related Syndromes. , 2017, , 211-224.		0
564	Actions to be taken for improving functional prognosis in dementia. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120156.	0.3	0
565	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts – ERRATUM. <i>British Journal of Psychiatry</i> , 2022, , 1-2.	1.7	0
566	Examination of cognitive performance and mild behavioral impairment domains of apathy, mood, impulse dyscontrol, social inappropriateness and psychosis in cognitively normal adults aged 50 and over. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
567	Long-term cognitive and motor decline across the spectrum of Lewy body disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
568	Hypertension, brain training and cognition in the healthy adults aged over 50 years: An online longitudinal study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
569	Repeated concussions associated with worsened working memory, attention and processing speed, but preserved delayed memory: A PROTECT study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
570	A randomised placebo-controlled study on the effects of anthocyanins for maintaining cognitive functioning in individuals at increased risk for dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
571	Associations between amygdala volume and trajectories of neuropsychiatric symptoms in Alzheimer's disease and dementia with Lewy Bodies. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0